 |
Navigation for the Antibiotic/Antimicrobial Resistance Website
• Specific Topics
• Antimicrobial Resistance Programs
|
|
| Antibiotic / Antimicrobial Resistance |
|
|
| Home > Clinical Guidelines |
|
Clinical Guidelines
| Healthcare-Associated Infections |
 |
Recommendations for Preventing the Spread of Vancomycin Resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
Morbidity and Mortality Weekly Report (MMWR). September 22, 1995;44(RR12):1-13.
(Also available in PDF format [212 KB, 20 pages].) |
|
Interim Guidelines for Prevention and Control of Staphylococcal Infection Associated with Reduced Susceptibility to Vancomycin
Morbidity and Mortality Weekly Report (MMWR). July 11, 1997;46(27):626-628, 635.
(Also available in PDF format [246 KB, 20 pages].) |
|
Guidelines and Recommendations for Hospital-Related Infections |
| Malaria |
|
Availability and Use of Parenteral Quinidine Gluconate for Severe or Complicated Malaria
Since 1991, quinidine gluconate, a class 1a anti-arrhythmic agent, has been the only parenteral antimalarial available for use in the United States. It is indicated for the treatment of patients with life-threatening Plasmodium falciparum malaria, including those who cannot tolerate oral therapy, have high-grade parasitemia, or have complications (e.g., cerebral malaria or acute renal failure). The limited availability of and delays in obtaining quinidine gluconate have contributed to adverse patient outcomes. As newer anti-arrhythmics have replaced quinidine for many cardiac indications, some hospitals and other health-care facilities have dropped quinidine gluconate from their formularies and, as a result, fewer clinicians have had experience using the drug. Discussions among quinidine gluconate manufacturer Eli Lilly Company (Indianapolis, Indiana), CDC, the U.S. Department of Defense, and the U.S. Food and Drug Administration have resulted in the following recommendations to improve quinidine gluconate availability for acutely ill malaria patients in U.S. health-care facilities.
Morbidity and Mortality Weekly Report (MMWR). December 22, 2000;49(50):1138-1140.
(Also available in PDF format [200 KB, 24 pages].) |
|
Information for Health Care Providers: MalaroneT for Malaria Treatment and Prophylaxis (October 27, 2000)
MalaroneT (a fixed combination of atovaquone and proguanil hydrochloride) is a new antimalarial drug approved in the United States in July 2000 for both treatment and prophylaxis of malaria. Malarone has been shown to be highly efficacious in the treatment of uncomplicated malaria caused by Plasmodium falciparum, including malaria that has been acquired in areas with chloroquine-resistant or multidrug-resistant strains. |
| Sexually Transmitted Diseases |
|
Sexually Transmitted Diseases Treatment Guidelines 2006 |
| Tuberculosis |
|
Fact Sheet: Treatment of Drug-Resistant Tuberculosis |
|
Management of Persons Exposed to Multidrug-Resistant Tuberculosis
Morbidity and Mortality Weekly Report (MMWR). June 19, 1992;41(RR-11):59-71. |
| Sources for Guidelines |
|
NCID Infectious Disease Guidelines
Links to professional guidelines published by NCID for the prevention, treatment, surveillance, and control of infectious diseases. |
|
National Guideline Clearinghouse™
A public resource for evidence-based clinical practice guidelines. NGC is sponsored by the Agency for Healthcare Research and Quality (AHRQ). |
|
Note: These sites are not CDC sites and will be opened in a new browser window. CDC is not
responsible for the content of Web pages found at these links. Links to nonfederal organizations
are provided solely as a service to our users. These links do not indicate an endorsement of these
organizations by CDC or the federal government. |
|
| |
| |
Date: July 15, 2008
Content source: National Center for Preparedness, Detection, and Control of Infectious Diseases/Division of Healthcare Quality Promotion |
|
